Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, today announced that a poster describing the design of the ongoing Phase I/II trial of BT8009 will be presented during an e-poster session at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 19-21, 2020. BT8009 is a second-generation Bicycle Toxin Conjugate (BTC), which uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload. BT8009 targets Nectin-4, a tumor antigen observed to be overexpressed in several common tumor types and associated with poor disease prognosis.

“We believe BT8009 represents an important addition to the landscape of potential next-generation treatments for patients with Nectin-4-positive cancers, as it could improve on Nectin-4-targeted therapies that are based on conventional modalities,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. “With our recent announcement that the first patient has been dosed in the Phase I/II trial of BT8009, we are pleased that the trial is progressing and look forward to providing an overview of its design at ESMO.”

Details on Bicycle’s poster presentation at ESMO are as follows:

Poster Title: BT8009-100 Phase I/II Study of the Safety, Pharmacokinetics, & Preliminary Clinical Activity of BT8009 in Patients with Nectin-4 Expressing Advanced Malignancies
Abstract #: 3716
Presentation #: 599TiP

The poster will be available on the ESMO website, as well as in the Publications section of bicycletherapeutics.com, beginning Thursday, September 17.

About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. BT8009 is a BTC targeting Nectin-4, a well-validated tumor antigen, and is also currently being evaluated a Company-sponsored Phase I/II trial. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.